This program is supported by an independent education grant from Pfizer. This online education program has been designed solely for healthcare professionals in the US.

In this virtual webinar, leading experts Dr Shawn Dason, MD, Dr Andrew Laccetti, MD and Dr Alicia Morgans, MD, MPH explore real-world clinical decision-making in metastatic prostate cancer (mPC) through an interactive, case-based roundtable. Designed to mirror multidisciplinary practice, the session guides healthcare providers through evolving patient scenarios—focusing on integrating homologous recombination repair (HRR) testing into clinical workflows, applying emerging PARP inhibitor (PARPi) combination evidence across mCSPC and mCRPC, and implementing proactive strategies to manage treatment toxicities and maintain care continuity.

Credits: 1 AMA PRA Category 1 Credits™ (1.00.00 hours)

Session Highlights

• Implementing HRR Testing in Clinical Practice: Practical guidance on workflow integration, optimizing testing timing, clarifying team ownership, and streamlining multidisciplinary coordination for result interpretation.
• Applying PARPi Evidence to Treatment Decisions: Case-based evaluation of clinical data to inform the selection, rationale, and sequencing of PARPi-based combination strategies across mCSPC and mCRPC.
• Managing Toxicity and Sustaining Treatment: Proactive dose-modification strategies and multidisciplinary coordination protocols to mitigate PARPi-related adverse events and maintain long-term treatment continuity.
• Interactive Real-World Expert Q&A: Audience-driven discussion addressing everyday clinical hurdles, care coordination barriers in community settings, and actionable solutions across the mPC care pathway.

Who Should Watch

This program is designed for healthcare professionals involved in mPC care across community and academic settings, including testing, treatment decision-making, and combination therapy management:

• Oncology and urology practitioners (academic and community)
• Oncology nurses and nurse practitioners
• Physician assistants
• Pharmacists
• Genetic counselors

Presented by

Dr Shawn Dason, MD is a urologic oncologist and Associate Clinical Professor of Urology at The Ohio State University College of Medicine and the OSUCCC – James, specializing in high-volume open and robotic surgeries for complex kidney, prostate, and testicular cancers. An expert in advanced vascular and retroperitoneal procedures such as IVC thrombectomy and RPLND, he prioritizes a patient-centered, multidisciplinary approach tailored to each individual's goals and needs. A Castle Connolly Top Doctor and AUA Research Scholar Award recipient, Dr. Dason actively advances urologic oncology through clinical education, serving on multiple editorial boards, and authoring over 70 peer-reviewed publications.

Dr Andrew Laccetti, MD, is a genitourinary medical oncologist at the Perlmutter Cancer Center at NYU Langone and Director of Quality for Hematology and Medical Oncology at NYU Langone Hospital—Long Island. Trained at MD Anderson Cancer Center and bringing over six years of prior experience at Memorial Sloan Kettering Cancer Center, he specializes in personalized care for prostate, kidney, bladder, and testicular cancers, with a focus on shared decision-making and quality of life. An active clinical investigator, Dr. Laccetti designs novel therapeutic trials and pioneers digital health innovations—such as remote monitoring via wearable activity trackers—to improve treatment safety, optimize side-effect management, and advance quality and equity across cancer care.

Dr Alicia Morgans, MD, MPH is a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association, and is a member of the cardio-oncology committee of the American Heart Association. Since 2016, she has been President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Shawn Dason, MD, has disclosed that he has no financial interests or relationships with any ineligible companies within the past 24 months. This disclosure is provided in accordance with ACCME Standards for Integrity and Independence to ensure transparency and uphold the integrity of continuing education.

Dr Shawn Dason, MD, does not intend to reference any unlabeled or unapproved uses of products during this presentation.

Dr Andrew Laccetti, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for Bayer, Johnson & Johnson, and Pfizer.Consultant for Bayer and Pfizer (podcast recording). Grant/Research Support from Bayer, JANUX Pharmaceuticals, Johnson & Johnson, and Novartis. These disclosures are provided in accordance with ACCME Standards for Integrity and Independence to ensure transparency and uphold the integrity of continuing education.

Dr Andrew Laccetti, MD, does not intend to reference any unlabeled or unapproved uses of products during this presentation.

Dr Alicia Morgans, MD, MPH, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Astellas, AstraZeneca, Bayer, Clarity, Curium, Lantheus, Merck, Novartis, Pfizer, Sumitomo, Telix, and Tolmar. These disclosures are provided in accordance with ACCME Standards for Integrity and Independence to ensure transparency and uphold the integrity of continuing education.

Dr Alicia Morgans, MD, MPH, does not intend to reference any unlabeled or unapproved uses of products during this presentation.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting September 2nd 2026 and will expire on September 2nd 2026. Estimated time to complete this activity: 60 minutes.